An interventional study of High-Intensity Peripheral Magnetic Stimulation and Sham Peripheral Magnetic Stimulation in Peripheral Nerve Injuries, Traumatic Peripheral Nerve Injury and Neuropathic Pain, sponsored by Gaziler Physical Medicine and Rehabilitation Education and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · Not applicable, Interventional, and Treatment
Traumatic peripheral nerve injury is a common cause of chronic neuropathic pain, muscle weakness, and functional limitation, particularly in young and active individuals. Current conservative and pharmacological treatments often provide incomplete relief or carry side effects. High-intensity peripheral magnetic stimulation (PMS) is a non-invasive method that may help reduce neuropathic pain and support motor recovery, but evidence in traumatic nerve injury is limited.
This randomized, double-blind, sham-controlled trial aims to evaluate whether high-intensity PMS, added to a standardized therapeutic exercise program, improves pain, function, quality of life, and electrophysiological measures in adults with traumatic peripheral nerve injury. Participants will be randomly assigned to receive either active PMS or sham PMS, in addition to the same exercise program. Outcomes will be assessed at baseline, 4 weeks, and 8 weeks.
This is a prospective, randomized, double-blind, sham-controlled clinical trial conducted at a single center. Adults aged 18-65 years with unilateral traumatic peripheral nerve injury confirmed by electromyography, with symptom onset at least 3 months prior, neuropathic pain (DN4 ≥ 4), pain severity (VAS ≥ 4), and reduced muscle strength (MRC \< 5) will be enrolled.
Participants will be randomly allocated using computer-generated randomization to one of two groups: (1) active high-intensity PMS plus a standardized therapeutic exercise program, or (2) sham PMS plus the same exercise program. Active stimulation will be delivered using a high-intensity magnetic stimulation system with a predefined neuropathy protocol (approximately 10 minutes per session, variable frequencies 1-60 Hz) applied over the injured peripheral nerve, for a total of 9 sessions over 3 weeks (3 sessions per week). In the sham group, the applicator coil will be reversed to prevent effective delivery of the magnetic field, while device screen and audible feedback are maintained. Both groups will receive an individualized exercise program (active range of motion, strengthening, stretching, proprioception and balance exercises, and occupational therapy) for 20 minutes per day, 5 days per week, over 3 weeks.
Participants and outcome assessors will be blinded to group allocation. The physiotherapist delivering the intervention will be aware of allocation but will not participate in assessments. Electrophysiological evaluations will be performed by a blinded electroneurophysiologist.
The primary outcome is pain severity measured by the Visual Analog Scale (VAS). Secondary outcomes include the Douleur Neuropathique 4 (DN4) questionnaire, the Brief Pain Inventory (BPI), the Nottingham Health Profile (NHP), Manual Muscle Testing (MRC scale), and electrophysiological parameters including compound muscle action potential (CMAP) amplitude, distal latency, nerve conduction velocity (NCV), and quantitative motor unit potential (MUP) analysis. Assessments will be performed at baseline (week 0), week 4, and week 8. A total of 40 participants (20 per group) is planned based on an a priori sample size calculation.
90 studies on the registry are indexed under Peripheral Nerve Injuries; 24 are open to participants now.
This study's planned enrollment of 40 is below the median of 46 across 62 interventional studies indexed under Peripheral Nerve Injuries.
Browse Peripheral Nerve Injuries studies →Gaziler Physical Medicine and Rehabilitation Education and Research Hospital is the lead sponsor of 85 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive high-intensity peripheral magnetic stimulation (PMS) applied over the injured peripheral nerve using a predefined neuropathy protocol (approximately 10 minutes per session, variable frequencies 1-60 Hz), for a total of 9 sessions over 3 weeks (3 sessions per week). Stimulation intensity is increased until motor activity is elicited and kept constant during the session. In addition, participants receive a standardized therapeutic exercise program (active range of motion, strengthening, stretching, proprioception and balance exercises, and occupational therapy) for 20 minutes per day, 5 days per week, over 3 weeks.
Device: High-Intensity Peripheral Magnetic Stimulation · Other: Therapeutic Exercise Program
Participants receive sham peripheral magnetic stimulation using the same device, session duration, and application site, but with the applicator coil reversed to prevent effective delivery of the magnetic field to the target tissue. Device screen and audible feedback are maintained to preserve blinding. In addition, participants receive the same standardized therapeutic exercise program (active range of motion, strengthening, stretching, proprioception and balance exercises, and occupational therapy) for 20 minutes per day, 5 days per week, over 3 weeks.
Device: Sham Peripheral Magnetic Stimulation · Other: Therapeutic Exercise Program
High-intensity peripheral magnetic stimulation delivered via an inductive coil placed over the injured peripheral nerve, using a predefined neuropathy protocol (approximately 10 minutes per session, variable frequencies 1-60 Hz). Stimulation intensity is increased until motor activity is elicited and kept constant during the session. Applied 3 times per week for 3 weeks (9 sessions total).
Sham peripheral magnetic stimulation using the same device, session duration, and application site, with the applicator coil reversed to prevent effective delivery of the magnetic field to the target tissue. Device screen and audible feedback are maintained to preserve blinding. Applied 3 times per week for 3 weeks (9 sessions total).
Standardized individualized therapeutic exercise program including active range of motion exercises, strengthening exercises, stretching exercises, proprioception and balance exercises, and occupational therapy for activities of daily living. Delivered for 20 minutes per day, 5 days per week, over 3 weeks.
Change in Pain Severity Measured by Visual Analog Scale (VAS)
Pain severity assessed using the Visual Analog Scale (VAS), a 0-10 cm scale where 0 indicates "no pain" and 10 indicates "unbearable pain." Higher scores indicate greater pain severity.
Time frame: Baseline, week 4, and week 8
Change in Neuropathic Pain Assessed by Douleur Neuropathique 4 (DN4)
Neuropathic pain assessed using the Douleur Neuropathique 4 questionnaire, a 10-item instrument based on patient-reported symptoms and clinical examination findings. Scores range from 0 to 10, with a total score of 4 or higher indicating neuropathic pain. Higher scores indicate a worse outcome.
Time frame: Baseline, week 4, and week 8
Change in Pain Severity and Interference Assessed by Brief Pain Inventory (BPI)
Pain severity and pain interference assessed using the Brief Pain Inventory Short Form. Pain severity is scored from 0 to 10 (0 = no pain, 10 = pain as bad as you can imagine) and pain interference is scored from 0 to 10 (0 = does not interfere, 10 = completely interferes) across general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher scores indicate a worse outcome.
Time frame: Baseline, week 4, and week 8
Change in Health-Related Quality of Life Assessed by Nottingham Health Profile (NHP)
Health-related quality of life assessed using the Nottingham Health Profile. Each of the six sections (pain, physical mobility, energy level, sleep, social isolation, and emotional reactions) is scored from 0 to 100. Higher scores indicate a worse outcome (greater impairment in quality of life).
Time frame: Baseline, week 4, and week 8
Change in Muscle Strength Assessed by Manual Muscle Testing (MRC Scale)
Muscle strength assessed by manual muscle testing using the Medical Research Council scale in muscle groups innervated by the affected peripheral nerve. Scores range from 0 (no visible contraction) to 5 (full strength against resistance). Higher scores indicate a better outcome.
Time frame: Baseline, week 4, and week 8
Change in Compound Muscle Action Potential (CMAP) Amplitude
CMAP amplitude of the affected nerve measured by nerve conduction studies, reported in millivolts (mV). Higher values indicate better motor nerve function.
Time frame: Baseline, week 4, and week 8
Change in Distal Motor Latency
Distal motor latency of the affected nerve measured by nerve conduction studies, reported in milliseconds (ms). Higher values indicate worse nerve conduction.
Time frame: Baseline, week 4, and week 8
Change in Nerve Conduction Velocity (NCV)
Motor nerve conduction velocity of the affected nerve measured by nerve conduction studies, reported in meters per second (m/s). Higher values indicate better nerve conduction.
Time frame: Baseline, week 4, and week 8
Change in Mean Motor Unit Potential (MUP) Duration
Mean duration of motor unit potentials in the affected muscle, assessed by quantitative needle electromyography and reported in milliseconds (ms). Increased duration indicates chronic reinnervation.
Time frame: Baseline, week 4, and week 8
Change in Mean Motor Unit Potential (MUP) Amplitude
Mean amplitude of motor unit potentials in the affected muscle, assessed by quantitative needle electromyography and reported in microvolts (µV). Increased amplitude indicates chronic reinnervation.
Time frame: Baseline, week 4, and week 8
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.
Of 26 interventional studies with no phase under Peripheral Nerve Injuries, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital